These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6488679)

  • 1. Effect of oral dose size on hydralazine kinetics and vasodepressor response.
    Shepherd AM; Irvine NA; Ludden TM; Lin MS; McNay JL
    Clin Pharmacol Ther; 1984 Nov; 36(5):595-600. PubMed ID: 6488679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of food on blood hydralazine levels and response in hypertension.
    Shepherd AM; Irvine NA; Ludden TM
    Clin Pharmacol Ther; 1984 Jul; 36(1):14-8. PubMed ID: 6734044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentration and acetylator phenotype determine response to oral hydralazine.
    Shepherd AM; McNay JL; Ludden TM; Lin MS; Musgrave GE
    Hypertension; 1981; 3(5):580-5. PubMed ID: 7298112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of response to intravenous hydralazine in hypertension.
    Shepherd A; Lin MS; McNay J; Ludden T; Musgrave G
    Clin Pharmacol Ther; 1981 Dec; 30(6):773-81. PubMed ID: 7307426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of hydralazine elimination.
    Talseth T
    Clin Pharmacol Ther; 1977 Jun; 21(6):715-20. PubMed ID: 862310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability of plasma hydralazine concentrations in male hypertensive patients.
    Ludden TM; McNay JL; Shepherd AM; Lin MS
    Arthritis Rheum; 1981 Aug; 24(8):987-93. PubMed ID: 7284051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of systemic availability of oral hydralazine in heart failure.
    Crawford MH; Ludden TM; Kennedy GT
    Clin Pharmacol Ther; 1985 Nov; 38(5):538-43. PubMed ID: 4053489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oral hydralazine in chronic heart failure.
    Hanson A; Johansson BW; Wernersson B; Wåhlander LA
    Eur J Clin Pharmacol; 1983; 25(4):467-73. PubMed ID: 6653641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasma norepinephrine accompanies persistent tachycardia after hydralazine.
    Lin MS; McNay JL; Shepherd AM; Musgrave GE; Keeton TK
    Hypertension; 1983; 5(2):257-63. PubMed ID: 6826216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on hydralazine. III. Bioavailability of hydralazine in man.
    Talseth T
    Eur J Clin Pharmacol; 1976; 10(6):395-401. PubMed ID: 1001354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
    Carlsen JE; Kardel T; Lund JO; McNair A; Trap-Jensen J
    Clin Pharmacol Ther; 1985 Mar; 37(3):253-9. PubMed ID: 2857601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of hydralazine and its main metabolites in slow and fast acetylators.
    Reece PA; Cozamanis I; Zacest R
    Clin Pharmacol Ther; 1980 Dec; 28(6):769-78. PubMed ID: 7438692
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and tolerability of hydralazine, in conventional and slow-release preparations, during long-term treatment of primary hypertension.
    Lins LE; Berglund J; Eliasson K; Wernersson B
    Clin Ther; 1983; 5(3):251-9. PubMed ID: 6850719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of hydralazine action in hypertension.
    O'Malley K; Segal JL; Israili ZH; Boles M; McNay JL; Dayton PG
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):581-6. PubMed ID: 1102235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propranolol-hydralazine combination in essential hypertension.
    Stevens JD; Binstok G; Mullane JF; Woods JW; Pittman AW; del Greco F; Huang C; Morledge JH
    Clin Ther; 1983; 5(5):525-39. PubMed ID: 6352036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nitrendipine and hydralazine on plasma catecholamines in essential hypertension.
    Lopez LM; Mehta JL; Baz R; Aguila E
    Clin Pharmacol Ther; 1984 Oct; 36(4):444-50. PubMed ID: 6478732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension.
    McGoon MD; Seward JB; Vlietstra RE; Choo MH; Moyer TP; Reeder GS
    Br Heart J; 1983 Dec; 50(6):579-85. PubMed ID: 6652000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydralazine kinetics after single and repeated oral doses.
    Shepherd AM; Ludden TM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):804-11. PubMed ID: 7438695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of hydralazine plasma concentration to dosage and hypotensive action.
    Zacest R; Koch-Weser J
    Clin Pharmacol Ther; 1972; 13(3):420-5. PubMed ID: 5026380
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.